JPMorgan analyst Jessica Fye reiterated an Overweight rating and $10.00 price target on BioCryst Pharma (NASDAQ: BCRX)The analyst comments "We ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE